The EORTC-GI Group compared a regimen of Taxotere® and Gemzar® to a regimen of Taxetore® and Platinol® for the treatment of advanced or metastatic (80%) pancreatic cancer.
Researchers from Austria evaluated the effects of Gemzar® with or without Xeloda® in 83 patients with metastatic pancreatic cancer. These combinations are mroe active than gemcitabine alone but witout a survival impact. Gemcitabine with carboplatin has support in a phase II study published in 2006. It concludes: ” The combination of gemcitabine plus carboplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer. This regimen has an acceptable toxicity profile and provides a significant clinical benefit, and hence warrants further investigation.”
Practice guideline – http://www.cancercare.on.ca/pdf/pebc2-7s.pdf
nccn.org, pancreatic cancer
N. Xiros et al, Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group Annals of Oncology 2005 16(5):773-779;